Breaking News
Investing Pro 0
🚨 NDVA surged 43%. This AI Chipmaker Could Be Next See Analysis
Close

Imugene Ltd (IMU)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.105 +0.005    +5.00%
02/06 - Closed. Currency in AUD ( Disclaimer )
  • Volume: 12,249,739
  • Bid/Ask: 0.100 / 0.105
  • Day's Range: 0.100 - 0.105
Type:  Equity
Market:  Australia
ISIN:  AU000000IMU9 
Imugene Ltd 0.105 +0.005 +5.00%

Imugene Ltd Company Profile

 
Get an in-depth profile of Imugene Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

5

Equity Type

ORD

Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing a range of new immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its PD-1 B-cell immunotherapy (PD1-Vaxx), aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect. Its HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Its clinical trial candidates include VAXINIA (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.

Contact Information

Address 4-6 Bligh Street Suite 12.01
Level 12 Sydney, 2000
Australia
Phone -
Fax -

Top Executives

Name Age Since Title
Axel Hoos 52 2013 Independent Non-Executive Director
Leslie Chong - 2015 CEO, MD & Executive Director
Paul Edward-Alexander Hopper 65 2012 Executive Chairman
Pravin T. P. Kaumaya - 2018 Member of Scientific Advisory Board
Neil H. Segal - 2014 Member of Scientific Advisory Board
Yelena Y. Janjigian - 2016 Scientific Advisory Board Member
Ursula Wiedermann - 2015 Member of Scientific Advisory Board
Josep Tabernero - 2018 Member of Scientific Advisory Board
Peter Schmid - 2017 Member of Scientific Advisory Board
Yuman Fong - 2019 Chair of Oncolytic Virotherapy Scientific Advisory Board
Charles S. Walker - 2015 Independent Non-Executive Director
Tanios Bekaii-Saab - 2018 Member of Scientific Advisory Board
Jens W. Eckstein - 2019 Independent Non-Executive Director
Lesley Russell 61 2019 Independent Non-Executive Director
Rebecca Auer - - Member of Scientific Advisory Board
Prasad S. Adusumilli - 2019 Member of Scientific Advisory Board
Saul J. Priceman - - Member of Oncolytics Virotherapy Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

IMU Comments

Write your thoughts about Imugene Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Marcus Donevar
Marcus Donevar Apr 11, 2020 20:14
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What will happen after virus
Andre Lazarof
Andre Lazarof Nov 08, 2019 10:56
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Looking forward the AGM today. Time to sky rocket!
Brian Case
Brian Case Jul 03, 2018 21:19
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Just just need to get through the CR fluff.
shankar vishwanath
shankar vishwanath May 22, 2018 8:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this is about to explode, just waiting on some interim results now and if the results are good
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email